Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industries, today announced results for its fiscal 2013 second quarter.
Revenue for the second quarter totaled $13.7 million, a 12% increase from $12.2 million reported in the fiscal 2012 second quarter. Diluted earnings per share from continuing operations totaled $0.23 versus $0.11 in the prior-year period. On a non-GAAP basis, earnings per share from continuing operations were $0.20 in the 2013 second quarter.
Help employers find you! Check out all the jobs and post your resume.